Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioArctic

308.60 SEK+1.38 %19.11, 16.06
Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+1.38 %
+7.38 %
-4.34 %
-1.15 %
-0.71 %
+10.14 %
+36.19 %
+150.49 %
+964.14 %

BioArctic is a biopharmaceutical company focused on developing new treatments that address the causes of neurodegenerative diseases. Examples of diseases include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. BioArctic was founded in 2003 and is headquartered in Stockholm.

Read more
Market cap
27.39B SEK
Turnover
15.25M SEK
Revenue
2B
EBIT %
62.97 %
P/E
26.72
Dividend yield-%
0.65 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
If you are investing in a company whose goal is to find cures for diseases such as Alzheimer’s, Parkinson’s, and ALS, BioArctic is the right investment for you, as this company’s ambitions are certainly not lacking. In addition, there is evidence, as a drug called Lecanemab has actually...
8/28/2025, 10:21 AM
by Hawkmountdiver
7
About that valuation. What has been the share price development in recent years? A quick read suggests it looks good. If compared to Faron and Herantis companies, this is a safer investment target at this moment.
8/28/2025, 2:16 PM
by j.sälli
2
Brand new Q2 / 2025 below. bioarctic.com wkr0006-146.pdf 1682.08 KB
8/28/2025, 10:28 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.11
2026

Interim report Q3'26

17.2
2027

Annual report '26

Press release18.11.2026, 17.17

BioArctic: New three-year real-world data on Leqembi® presented at CTAD 2026

BioArctic
Press release18.11.2026, 08.30

Invitation to presentation of BioArctic's third quarter report for July - September 2026 on November 25 at 9:30 a.m. CET

BioArctic
Press release17.11.2026, 00.05

BioArctic: Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release13.11.2026, 08.00

BioArctic: Leqembi[®] Pen subcutaneous treatment launched in Japan

BioArctic
BioArctic AB, Q3'26
Webcast25.11.2026, 09.30

BioArctic AB, Q3'26

BioArctic
Regulatory press release02.11.2026, 21.30

BioArctic collaborator Novartis terminates agreement

BioArctic
Press release30.10.2026, 15.00

BioArctic's Nomination Committee appointed

BioArctic
Press release30.10.2026, 08.00

BioArctic: New clinical data on lecanemab to be presented at CTAD conference 2026

BioArctic
Press release29.10.2026, 12.21

Redeye: BioArctic: Leqembi Q3 royalties in line with estimates

BioArctic
Regulatory press release28.10.2026, 11.00

BioArctic: Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026

BioArctic
Press release23.09.2026, 16.10

Redeye: BioArctic (Q2 and pipeline review): Iqlik in focus

BioArctic
Press release22.09.2026, 16.10

BioArctic: First patient treated with Leqembi® (lecanemab) in Sweden

BioArctic
Regulatory press release16.09.2026, 08.05

BioArctic: Leqembi® Pen subcutaneous formulation approved in Japan

BioArctic
Regulatory press release03.09.2026, 06.00

BioArctic: Leqembi® subcutaneous formulation approved for initiation treatment in China

BioArctic
Press release01.09.2026, 07.00

BioArctic: Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

BioArctic
Regulatory press release31.08.2026, 17.30

Number of shares and votes in BioArctic AB (publ) as of August 31, 2026

BioArctic
BioArctic, Audiocast, Q2'26
Webcast26.08.2026, 09.30

BioArctic, Audiocast, Q2'26

BioArctic
Regulatory press release26.08.2026, 08.00

Interim Report for the period April - June 2026

BioArctic
Press release24.08.2026, 14.05

BioArctic: Leqembi Iqlik® for initiation treatment launched in the US

BioArctic
Press release21.08.2026, 14.00

Modular Finance IR Consensus: Estimates compiled by Modular Finance on behalf of BioArctic

BioArctic